Unicycive Therapeutics Reports $6.4 Million Net Loss in Q2 2025

Unicycive Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $6.4 million, a significant decrease from a net income of $9.9 million in the same period last year. The company’s total operating expenses for the quarter were approximately $7.0 million, down from $7.4 million in the prior year, primarily due to a 64% reduction in research and development expenses, which fell to $1.8 million from $4.9 million. General and administrative expenses, however, increased by 106% to $5.2 million, driven by higher marketing and consulting costs associated with the company's commercial launch efforts.

In terms of revenue, Unicycive did not report any product sales, as it continues to focus on the development of its drug candidates, including Oxylanthanum Carbonate and UNI-494. The company’s accumulated deficit increased to $107.1 million as of June 30, 2025, reflecting ongoing investment in research and development. The decrease in research expenses was attributed to a reduction in drug development costs, while the rise in general and administrative expenses was linked to increased operational activities as the company prepares for potential product launches.

Operationally, Unicycive has made strides in its financing activities, raising approximately $12.2 million through the sale of 2,009,616 shares of common stock at an average price of $6.07 per share during the first half of 2025. The company also executed a reverse stock split in June 2025, consolidating every ten shares into one, which is expected to enhance its stock price and market perception. As of June 30, 2025, the company had approximately 12.8 million shares outstanding, excluding shares issued for rounding fractional interests.

Looking ahead, Unicycive anticipates continued losses as it advances its clinical programs and seeks regulatory approvals. The company has indicated that it will require additional capital to fund its operations and clinical trials, with management expressing confidence in its ability to access capital through equity offerings or collaborations. However, there are no guarantees regarding the timing or terms of future financing, which could impact the company’s ability to execute its business strategy effectively.

Overall, Unicycive Therapeutics is navigating a challenging financial landscape while focusing on the development of innovative therapies for kidney disease. The company’s strategic decisions, including its recent financing activities and operational adjustments, will be critical as it aims to bring its product candidates to market and achieve long-term growth.